Skip to main content
SpringerLink
Log in

A Rationale for Antioxidant Use in Cardiovascular Disease

  • Chapter
Antioxidants and Cardiovascular Disease

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 233))

  • 125 Accesses

Abstract

Free radicals contribute to the pathogenesis of both acute (ischemia-reperfusion injury) and chronic (atherosclerosis) cardiovascular diseases. Prospective epidemiological studies have demonstrated a strong inverse relationship between serum antioxidant levels and the number of adverse events associated with coronary artery disease. The mechanistic rationale for this antioxidant benefit can be attributed to the “oxidative-modification hypothesis”, a model that proposes that certain inflammatory processes associated with atherogenesis are triggered by free radical-induced modification of lipids associated with low density lipoproteins and vascular cell membranes. Oxidative stress is also an important feature of heart failure; increasing levels of serum malondialdehyde, a product of lipid peroxidation, can be correlated with severity of disease. In this review, the basic mechanisms by which free radicals effect cell injury and the potential role for compounds with antioxidant activity to intervene in these disease processes will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rubin E, Farber JL. Cell injury. In: Rubin E, Farber JL, eds. Pathology, ed. 2. Philadelphia: J.B. Lippincott, 1994; 1–31.

    Google Scholar 

  2. Mason RP, Walter MF, Trumbore MW, Olmstead Jr. EG, Mason PE. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 1999; 31:275–281.

    Article  PubMed  CAS  Google Scholar 

  3. Mason RP, Rhodes DG, Herbette LG. Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. J Med Chem. 1991; 34:869–77.

    Article  PubMed  CAS  Google Scholar 

  4. Mason RP, Campbell SF, Wang SD, Herbette LG. Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes. Mol Pharmacol 1989; 36:634–40.

    PubMed  CAS  Google Scholar 

  5. Bauerle HD, Seelig J. Interaction of charged and uncharged calcium channel antagonists with phospholipid membranes. Binding equilibrium, binding enthalpy, and membrane location. Biochemistry 1991; 30:7203–11.

    Article  PubMed  CAS  Google Scholar 

  6. Burges RA, Gardiner DG, Gwilt M, et al. Calcium channel blocking properties of amlodipine in vascular smooth muscle and cardiac muscle in vitro: Evidence for voltage modulation of vascular dihydropyridine receptors. J Cardiovasc Pharmacol 1987; 9:110–9.

    PubMed  CAS  Google Scholar 

  7. Kass RS, Arena JP. Influence of,pH on calcium channel block by amlodipine, a charged dihydropyridine compound. Implications for location of the dihydropyridine receptor. J Gen Physiol 1989; 93:1109–27.

    Article  PubMed  CAS  Google Scholar 

  8. Mak IT, Weglicki WB. Comparative antioxidant activities of propranolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation. Cire Res 1990; 66:1449–52.

    Article  CAS  Google Scholar 

  9. Mak IT, Boehme P, Weglicki WB. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells: Correlation of protection with preservation of glutathione levels. Circ Res 1992; 70:1099–103.

    Article  PubMed  CAS  Google Scholar 

  10. Janero DR, Burghardt B, Lopez R. Protection of cardiac membrane phospholipid against oxidative injury by calcium antagonists. Biochem Pharmacol 1988; 37:4197–203.

    Article  PubMed  CAS  Google Scholar 

  11. Ondrias K, Misik V, Gergel D, Stasko A. Lipid peroxidation of phosphatidylcholine liposomes depressed by the calcium channel blockers nifedipine and verapamil and by the antiarrhythmic-antihypoxic drug stobadine. Biochim Biophys Acta 1989; 1003:238–45.

    Article  PubMed  CAS  Google Scholar 

  12. Byington RP, Miller ME, Herrington D, et al. Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). Am J Cardiol 1997; 80:1087–90.

    Article  PubMed  CAS  Google Scholar 

  13. Byington RP, Chen J, Furberg CD, Pitt B. Effect of amlodipine on cardiovascular events and procedures. J Am Coll Cardiol 1999; 33:314A.

    Google Scholar 

  14. Diaz-Velez CR, Garcia-Castineiras S, Mendoza-Ramos E, Hernandez-Lopez E. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am Heart J 1996; 131:146–52.

    Article  PubMed  CAS  Google Scholar 

  15. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992; 263:92–8.

    PubMed  CAS  Google Scholar 

  16. Lysko PG, Lysko KA, Webb CL, et al. Neuroprotective activities of carvedilol and a hydroxylated derivative. Biochem Pharmacol 1998; 56:1645–56.

    Article  PubMed  CAS  Google Scholar 

  17. Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335:1107–14.

    Article  PubMed  CAS  Google Scholar 

  18. Mason RP, Leeds PR, Jacob RF, et al. Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells. J Neurochem 1999; 72:1448–56.

    Article  PubMed  CAS  Google Scholar 

  19. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997; 336:1131–41.

    Article  PubMed  CAS  Google Scholar 

  20. Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996; 335:1182–9.

    Article  PubMed  CAS  Google Scholar 

  21. Mason RP, Walter MF, Mason PE. Effect of oxidative stress on membrane structure: Small angle x-ray diffraction analysis. Free Radic Biol Med 1997; 23:419–25.

    Article  PubMed  CAS  Google Scholar 

  22. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that incease its atherogenicity. N.Engl J Med 1989; 320:915–24.

    Article  PubMed  CAS  Google Scholar 

  23. Steinbrecher UP, Lougheed M, Kwan WC, Dirks M. Recognition of oxidized low density lipoprotein by the scavenger receptor of macrophages results from derivatization of apolipoprotein B by products of fatty acid peroxidation. J Biol Chem 1989; 264:15216–23.

    PubMed  CAS  Google Scholar 

  24. Frostegard J, Haegerstrand A, Gidlund M, Nilsson J. Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis 1991; 90:119–26.

    Article  PubMed  CAS  Google Scholar 

  25. Schwartz CJ, Valente Ai, Sprague EA, Kelley JL, Nerem RM. The pathogenesis of atherosclerosis: An overview. Clin Cardiol 1991; 14:11–116.

    Article  Google Scholar 

  26. Cathcart MK, Morel DW, Chisolm GM, III. Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. J Leukoc Biol 1985; 38:341–50.

    PubMed  CAS  Google Scholar 

  27. Palinski W, Rosenfeld ME, Yla-Herttuala S, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989; 86:1372–6.

    Article  PubMed  CAS  Google Scholar 

  28. Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339:883–7.

    Article  PubMed  CAS  Google Scholar 

  29. Holvoet P, Perez G, Zhao Z, et al. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 1995; 95:2611–9.

    Article  PubMed  CAS  Google Scholar 

  30. Reaven PD, Parthasarathy S, Beltz WF, Witztum JL. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. Arterioscler Thromb 1992; 12:318–24.

    Article  PubMed  CAS  Google Scholar 

  31. Floyd RA, Schneider JE. Hydroxy free radical damage to DNA. In: Vigo-Pelfrey C, ed. Membrane Lipid Oxidation, vol. I. Boca Raton, Florida: C.R.C. Press, 1990.

    Google Scholar 

  32. Brawn K, Fridovich 1. DNA strand scission by enzymically generated oxygen radicals. Arch. Biochem Biophys 1981; 206:414–9.

    Article  CAS  Google Scholar 

  33. Oliver CN, Starke-Reed PE, Stadtman ER, et al. Oxidative damage to brain proteins, loss of glutamine synthetase activity, and production of free radicals during ischemia/reperfusioninduced injury to gerbil brain. Proc Natl Acad Sci USA 1990; 87:5144–7.

    Article  PubMed  CAS  Google Scholar 

  34. Belcher JD, Balla J. Balla G, et al. Vitamin E, LDL, and endothelium. Brief oral vitamin supplementation prevents oxidized LDL-mediated vascular injury in vitro. Arterioscler Thromb 1993; 13:1779–89.

    Article  PubMed  CAS  Google Scholar 

  35. Sasahara M, Raines EW, Chait A, et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest 1994; 94:155–64.

    Article  PubMed  CAS  Google Scholar 

  36. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol ur related to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectivel/inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the I rogression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987; 84:7725–9.

    CAS  Google Scholar 

  37. Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restonosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 1997; 337:365–72.

    Article  PubMed  CAS  Google Scholar 

  38. Chin JH, Azhar S, Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992; 89:10–8.

    Article  PubMed  CAS  Google Scholar 

  39. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990: 344:160–2.

    Article  PubMed  CAS  Google Scholar 

  40. Kugiyama K, Ohgushi M, Sugiyama S, et al. Lysophosphatidylcholine inhibits surface receptor-mediated intracellular signals in endothelial cells by a pathway involving protein kinase C activation. Circ Res 1992; 71:1422–8.

    Article  PubMed  CAS  Google Scholar 

  41. Levine GN, Keaney JE, Jr., Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995; 332:512–21.

    Article  PubMed  CAS  Google Scholar 

  42. Plane F, Jacobs M, McManus D, Bruckdorfer KR. Probucol and other antioxidants prevent the inhibition of endothelium-dependent relaxation by low density lipoproteins. Atherosclerosis 1993: 103:73–9.

    Article  PubMed  CAS  Google Scholar 

  43. Ross R. Atherosclerosis -- An inflammatory disease. N Engl J Med 1999; 340:115–26.

    Article  PubMed  CAS  Google Scholar 

  44. Stephens NG, Parson A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347:781–6.

    PubMed  CAS  Google Scholar 

  45. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328:1450–6.

    Article  PubMed  Google Scholar 

  46. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328:1450–6.

    Article  PubMed  CAS  Google Scholar 

  47. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 1992; 3:194–202.

    Article  PubMed  CAS  Google Scholar 

  48. Riemersma RA, Wood DA, Macintyre CC, et al. Low plasma vitamins E and C. Increased risk of angina in Scottish men. Ann N Y Acad Sci 1989; 570:291–5.

    Article  PubMed  CAS  Google Scholar 

  49. Ramirez J, Flowers NC. Leukocyte ascorbic acid and its relationship to coronary artery disease in man. Am J Clin Nutr 1980; 33:2079–87.

    PubMed  CAS  Google Scholar 

  50. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334:1145–9.

    Article  PubMed  CAS  Google Scholar 

  51. The Alpha-Tocopherol BCCPSG. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330:1029–35.

    Article  Google Scholar 

  52. Losonczy KG, Harris TB, Havlik RJ. Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: The Established Populations for Epidemiologic Studies of the Elderly. Am J Clin Nutr 1996; 64:190–6.

    PubMed  CAS  Google Scholar 

  53. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer’s disease. Neurology 1995; 45:1594–601.

    Article  PubMed  CAS  Google Scholar 

  54. Smith CD, Carney JM, Starke-Reed PE, et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA 1991; 88:10540–3.

    Article  PubMed  CAS  Google Scholar 

  55. Betel C, Davis J, Cole GM, Schubert D. Vitamin E protects nerve cells from amyloid 13-protein toxicity. Biochem Biophys Res Commun 1992; 186:944–50.

    Article  Google Scholar 

  56. Behl C, Skutella T, Lezoualc’h F, et al. Neuroprotection against oxidative stress by estrogens: Structure-activity relationship. Mol Pharmacol 1997; 51:535–41.

    PubMed  CAS  Google Scholar 

  57. Hensley K, Carney JM, Mattson MP, et al. A model for (3-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Nat1 Acad Sci USA 1994; 91:3270–4.

    Article  CAS  Google Scholar 

  58. Benzi G, Moretti A. Are reactive oxygen species involved in Alzheimer’s disease? Neurobiol Aging 1995; 16:661–74.

    Article  PubMed  CAS  Google Scholar 

  59. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med 1997; 336:1216–22.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. R. Preston Mason
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Montreal Heart Institute, Research Center and Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada

    Jean-Claude Tardif  & Martial G. Bourassa  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Mason, R.P. (2000). A Rationale for Antioxidant Use in Cardiovascular Disease. In: Tardif, JC., Bourassa, M.G. (eds) Antioxidants and Cardiovascular Disease. Developments in Cardiovascular Medicine, vol 233. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4375-2_10

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-4375-2_10

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-5881-0

  • Online ISBN: 978-94-011-4375-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation